This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Notario, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Notario, G. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3381-3384, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01588-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Molecular Characterization of Staphylococcus aureus Isolates from a 2005 Clinical Trial of Uncomplicated Skin and Skin Structure Infections{triangledown}

Ronald N. Jones,1,2* Angela M. Nilius,3 Bolanle K. Akinlade,3 Lalitagauri M. Deshpande,1 and Gerard F. Notario3

JMI Laboratories, North Liberty, Iowa,1 Tufts University School of Medicine, Boston, Massachusetts,2 Abbott Laboratories, Abbott Park, Illinois3

Received 20 December 2006/ Returned for modification 10 March 2007/ Accepted 13 June 2007

A clinical trial of uncomplicated skin and skin structure infections (39 locations in 19 states) observed that community-associated or community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) represented 23% of all pathogens at baseline culture and 53% of 190 S. aureus isolates. CO-MRSA strains typically were Panton-Valentine leukocidin (PVL) positive (95%), contained staphylococcal cassette chromosome mec type IVa (99%), were USA300 or USA400 clones (92%), and exhibited minimal coresistances (macrolides and/or fluoroquinolones). Clinical results remained identical (89% cures) regardless of the antimicrobial used or CO-MRSA molecular patterns, PVL production, or antimicrobial susceptibility profiles.

* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: ronald-jones{at}jmilabs.com

{triangledown} Published ahead of print on 18 June 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3381-3384, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01588-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ge, Y., Biek, D., Talbot, G. H., Sahm, D. F. (2008). In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 3398-3407 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»